Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:11:15 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:MTNB from 2023-05-07 to 2024-05-06 - 26 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 07:00U:MTNBNews ReleaseMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
2024-04-30 08:00U:MTNBNews ReleaseIn Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
2024-04-03 08:30U:MTNBNews ReleaseMatinas BioPharma Prices $10 Million Registered Direct Offering
2024-03-27 16:05U:MTNBNews ReleaseMatinas BioPharma Reports 2023 Financial Results and Provides a Business Update
2024-03-25 08:00U:MTNBNews ReleaseMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
2024-03-22 09:15U:MTNBNews ReleaseThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
2024-03-22 06:30U:MTNBNews ReleaseMatinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
2024-02-26 08:00U:MTNBNews ReleaseMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
2024-02-20 07:30U:MTNBNews ReleaseMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
2024-01-03 07:00U:MTNBNews ReleaseMatinas BioPharma to Present at Biotech Showcase 2024
2023-12-27 07:30U:MTNBNews ReleaseMatinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
2023-12-21 07:30U:MTNBNews ReleaseMatinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
2023-11-08 16:05U:MTNBNews ReleaseMatinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
2023-11-07 07:30U:MTNBNews ReleaseMatinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
2023-11-01 07:00U:MTNBNews ReleaseMatinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
2023-10-11 07:30U:MTNBNews ReleasePatient with Candida krusei Infection in Matinas BioPharma ¢ € ™s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
2023-09-28 07:00U:MTNBNews ReleaseMatinas BioPharma to Present at Two Investment Conferences in October 2023
2023-09-27 07:00U:MTNBNews ReleaseMatinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
2023-09-22 17:25U:MTNBNews ReleaseMatinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
2023-09-06 07:00U:MTNBNews ReleaseMatinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
2023-08-22 07:30U:MTNBNews ReleaseMatinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
2023-08-09 16:05U:MTNBNews ReleaseMatinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
2023-08-02 07:00U:MTNBNews ReleaseMatinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
2023-07-26 08:00U:MTNBNews ReleaseMatinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
2023-05-11 07:30U:MTNBNews ReleaseMatinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
2023-05-10 16:05U:MTNBNews ReleaseMatinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update